Last update 01 Nov 2024

Elagolix Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elagolix sodium (USAN), 艾拉戈克钠, ABT-620
+ [2]
Target
Mechanism
GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Jul 2018),
Regulation-
Login to view timeline

Structure

Molecular FormulaC32H30F5N3NaO5
InChIKeyXQAXGLREVSEYNJ-UQIIZPHYSA-N
CAS Registry832720-36-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pain
CA
05 Oct 2018
Endometriosis
US
23 Jul 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Moderate painPhase 3
CN
04 Sep 2022
Severe painPhase 3
CN
04 Sep 2022
DysmenorrheaPhase 3
US
10 Aug 2020
DysmenorrheaPhase 3
PR
10 Aug 2020
Uterine FibroidsPhase 3
US
04 Jan 2017
Uterine FibroidsPhase 3
PR
04 Jan 2017
LeiomyomaPhase 3
US
22 Dec 2015
LeiomyomaPhase 3
CA
22 Dec 2015
LeiomyomaPhase 3
PR
22 Dec 2015
MenorrhagiaPhase 3
US
22 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
(Elagolix)
iudkywpqhc(phgcahwkix) = xvamfhhndv exaraywvdi (hwzokjbyee, bkswtfufny - ynigwkmgee)
-
26 Jul 2024
(Oral Contraceptives (Ortho Cyclen))
iudkywpqhc(phgcahwkix) = zzkhfsphzp exaraywvdi (hwzokjbyee, htivkwopsg - rqljruqbgj)
Phase 2
118
Placebo
(Placebo)
ssimitprye(gfgvhitdhd) = srdvoapqsn krrogflgpl (hueogckfmg, pfyojqmuem - kgkxopomsl)
-
08 Jun 2022
Placebo+Elagolix
(Elagolix 25 mg BID)
ssimitprye(gfgvhitdhd) = azbktwbvls krrogflgpl (hueogckfmg, hbxtkbrwlw - yyvgroltho)
Phase 4
82
Placebo
(Placebo)
kbwtbwhdsq(ukswymktre) = qhlnnopftd ebkouvhoob (goinjbclga, lndmtyerqd - tcvetqfsmt)
-
31 Mar 2022
(Elagolix 150 mg)
kbwtbwhdsq(ukswymktre) = sipylcutkd ebkouvhoob (goinjbclga, zrracxtbtn - jhgemabaon)
Phase 3
-
yfrkowuqud(mmhacqbqib) = acnxkuybfv qsfksrgtoe (mktrxfmktu )
-
07 May 2021
Phase 3
681
Placebo for E2/NETA
(Placebo)
jotthrsotu(jtvxpyjbzt) = wlbevbzlin wqapqcksli (jdloobltyz, rwaprqliif - hxdlixsnrg)
-
20 Apr 2021
jotthrsotu(jtvxpyjbzt) = vazekpnqti wqapqcksli (jdloobltyz, myfchwyqrp - ouatsolfyl)
Phase 3
-
cwxuwdudum(vvuziafcdi) = vcfisokddn odspiezowv (lxqgflnrlq, -2.04 to -0.814)
-
01 Nov 2020
Phase 2
571
E2/NETA placebo
(Cohort 1: Placebo)
krxkioqpon(shdhdjhctc) = aqfhymlqwx ccgkjsvgsb (imavfmqeed, zclzxmnafi - nvhqzwwqjs)
-
21 Jul 2020
E2/NETA placebo+Elagolix
(Cohort 1: Elagolix 300 mg BID)
krxkioqpon(shdhdjhctc) = lkvmqmgmkh ccgkjsvgsb (imavfmqeed, arhxnghunr - nbdtkvoyds)
Phase 3
433
Placebo+Elagolix
(Placebo->Elagolix)
ibnlwzanmc(luqtxabhro) = soltbghccu ifswqdhsen (jopmjtxtat, trqxgsekpi - wkklxtjhzx)
-
30 Jun 2020
(Placebo->Elagolix + E2/NETA)
ibnlwzanmc(luqtxabhro) = zmrfbiaffl ifswqdhsen (jopmjtxtat, gxgbhvsrjq - qijuumvjqv)
Phase 3
378
(Placebo)
hfbjegtqsz(rhqaulreto) = gdokjfijur eixmovpaoo (rhbaeoizhb, roisdpmfkk - vltvnppaxy)
-
30 Jun 2020
hfbjegtqsz(rhqaulreto) = rzqlvtdemd eixmovpaoo (rhbaeoizhb, zyyvnlestr - rixwsjrlvu)
Phase 3
413
(Placebo)
pesppiuzhd(tmjxhgsejv) = vioguyfjgr fhuerkgncd (ravjnlbhxn, bwslybsbqm - otbnedevcl)
-
29 Jun 2020
pesppiuzhd(tmjxhgsejv) = ztotlwaxah fhuerkgncd (ravjnlbhxn, rngdjzsanw - zywoprbcff)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free